XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Nano Tx Therapeutics [Member]
Series C Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B Convertible Preferred Stock [Member]
Convertible Preferred Stock [Member]
Series B and C Convertible Preferred Stock [Member]
Common Stock [Member]
Common Stock [Member]
Nano Tx Therapeutics [Member]
Common Stock [Member]
Series B Convertible Preferred Stock [Member]
Common Stock [Member]
Series B and C Convertible Preferred Stock [Member]
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Nano Tx Therapeutics [Member]
Additional Paid-in Capital [Member]
Series C Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2018 $ 5,225                   $ 418,390     $ 1,218 $ (414,383)
Balance (in shares) at Dec. 31, 2018       4,606     296,609                
Share-based compensation 127                   127        
Sale of common stock and pre-funded warrants, net of offering costs 4,421           $ 4       4,417        
Sale of common stock and pre-funded warrants, net of offering costs (in shares)             3,000,000                
Sale/Issuance of common stock 2,208                   2,208        
Sale/Issuance of common stock (in shares)             184,666                
Conversion of Convertible Preferred Stock into common stock (share)           (2,647)       334,199          
Exercise of warrants 490                   490        
Exercise of warrants (in shares)             65,114                
Warrant liability reclasssified to equity due to exercise of warrants 794                   794        
Beneficial conversion feature related to Series C Convertible Preferred Stock     $ 554                   $ 554    
Accretion of beneficial conversion feature related to Series C Convertible Preferred Stock     $ (554)                   $ (554)    
Foreign currency translation adjustment and accumulated other comprehensive income (1,218)                         $ (1,218)  
Net loss (10,887)                           (10,887)
Balance at Dec. 31, 2019 $ 1,160           $ 4       426,426       (425,270)
Balance (in shares) at Dec. 31, 2019 3,880,588     1,959     3,880,588                
Share-based compensation $ 247                   247        
Issuance of common stock, net of offering costs 3,882           $ 2       3,880        
Issuance of common stock, net of offering costs (share)             2,150,113                
Conversion of Convertible Preferred Stock into common stock (share)         (5)       37            
Exercise of warrants 1,098           $ 1       1,097        
Exercise of warrants (in shares)             487,521                
Warrant liability reclasssified to equity due to exercise of warrants 4,504                   4,504        
Issuance of common stock for in process research and development acquired   $ 381                   $ 381      
Issuance of common stock for in process research and development acquired (in share)               230,769              
Net loss (8,241)                           (8,241)
Balance at Dec. 31, 2020 $ 3,031           $ 7       $ 436,535       $ (433,511)
Balance (in shares) at Dec. 31, 2020 6,749,028     1,954     6,749,028